Jim Simons Verrica Pharmaceuticals Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 147,964 shares of VRCA stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

147,964

Previous 45,525 225.02%

Holding current value

$1.18 Million

Previous $331,000 255.29%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$7.95 - $7.95 $814,390 - $814,390	102,439 Added 225.02%	147,964 $1.18 Million
Q2 2024 Aug 09, 2024	BUY	$5.89 - $9.56 $268,142 - $435,219	45,525 New	45,525 $331,000
Q3 2023 Nov 14, 2023	SELL	$3.75 - $7.46 $342,000 - $680,352	-91,200 Reduced 57.25%	68,100 $265,000
Q2 2023 Aug 11, 2023	BUY	$5.32 - $6.79 $546,896 - $698,012	102,800 Added 181.95%	159,300 $919,000
Q1 2023 May 12, 2023	SELL	$2.88 - $8.51 $287,637 - $849,927	-99,874 Reduced 63.87%	56,500 $367,000
Q4 2022 Feb 13, 2023	SELL	$2.09 - $3.39 $154,505 - $250,609	-73,926 Reduced 32.1%	156,374 $430,000
Q3 2022 Nov 14, 2022	BUY	$2.17 - $4.3 $395,808 - $784,320	182,400 Added 380.79%	230,300 $672,000
Q2 2022 Aug 12, 2022	BUY	$1.81 - $8.93 $86,699 - $427,747	47,900 New	47,900 $92,000
Q1 2020 May 14, 2020	SELL	$7.14 - $16.86 $99,246 - $234,354	-13,900 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$13.08 - $17.43 $181,812 - $242,277	13,900 New	13,900 $221,000

Others Institutions Holding VRCA

# of Institutions

Shares Held

14.2M

Call Options Held

9.9K

Put Options Held

6.5K

View Full List

About Verrica Pharmaceuticals Inc.

Ticker VRCA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,094,100
Market Cap $327M
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...

More about VRCA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account